Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | DRD5 | P21918 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11648759 | 0.98 | SLC6A3 (0.52) | OPRM1OPRD1OPRK1OPRL1SLC6A3 | |
| SCHEMBL18306930 | 0.95 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1SLC6A3 | |
| SCHEMBL7824744 | 0.90 | OPRM1 (0.53) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL26929227 | 0.89 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1SLC6A3 | |
| SCHEMBL31322237 | 0.82 | DRD2 (0.58) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL1239660 | 0.81 | DRD2 (0.40) | OPRM1OPRD1OPRK1OPRL1SLC6A3 | |
| SCHEMBL3640272 | 0.80 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL615480 | 0.80 | DRD2 (0.66) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL24845287 | 0.80 | DRD2 (0.43) | OPRM1OPRK1OPRL1SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL1765160 | 0.79 | DRD2 (0.63) | OPRM1OPRD1OPRK1OPRL1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496890-A1 | SUBSTITUTED BETA-AMINOALCOHOLS USED AS MEDICAMENTS | Grünenthal GmbH (DE) | 2005-01-19 | — | — | EP | claimed |
| WO-2003051353-A1 | SUBSTITUTED BETA-AMINOALCOHOLS USED AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-06-26 | — | — | WO | claimed |
| US-20230161254-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230161254-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-9949968-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-04-24 | — | — | US | disclosed |
| US-9949968-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-04-24 | — | — | US | disclosed |
| US-9949968-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-04-24 | — | — | US | disclosed |
| EP-3055293-B1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-12-06 | — | — | EP | disclosed |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-05-18 | — | — | US | disclosed |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-05-18 | — | — | US | disclosed |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-05-18 | — | — | US | disclosed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | OPRM1 443/4885OPRD1 200/4885OPRK1 39/4885 |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | OPRM1 482/4885OPRD1 187/4885OPRK1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.